Autologous Bone Marrow Mononuclear Cell Transplantation in Treating Type 2 Diabetes Mellitus
A phase 1/2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1026 participants.
Also called NCT01677013
- Study
- In this atlas
Overview
- Design
- Interventional study; non-randomized; no masking; primary purpose treatment
- Phase
- Phase 1/2
- Enrolled
- 1,026 participants
- Sponsor
- Peking University Aerospace Center Hospital
- Registry
-
NCT01677013
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT01677013. Non-randomized; no masking; primary purpose treatment. Start 2011-05 (registry gives no type); primary completion 2015-05 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Autologous Bone Marrow Mononuclear Cell Transplantation in Treating Type 2 Diabetes Mellitus
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Other)
- BMMCT
- Lead sponsor
- Peking University Aerospace Center Hospital
Record details
- Record id
cardio:ct-nct01677013- Content hash
ec8b95666a378eafede754639318978833b7a71262125935e6fd9a128aa1e8ec